MedPath

Investigating the tolerability of a diet containing CAPRIDIN in patients with rectal cancer

Phase 1
Conditions
Rectal cancer, Ketogenic regimen.
Malignant neoplasm of rectum
Registration Number
IRCT20170211032494N4
Lead Sponsor
Tehran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
20
Inclusion Criteria

Patients aged 18 to 75 years old
Patients with definitive diagnosis of rectal adenocarcinoma according to histopathology
Patients with a Karnofsky score higher than 70
Non-metastatic patients
Locally advanced patients (T3, T4) N0 or N+
Patients with BMI between 18-34

Exclusion Criteria

Patients with metabolic diseases
Pregnancy
Liver or kidney dysfunction
Receiving neoadjuvant chemotherapy
Patients who have undergone rectal cancer surgery for any reason
Breastfeeding
No previous ketogenic diet

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Tolerability: not interrupting the ketogenic diet for more than 4 consecutive days or 8 non-consecutive days. Timepoint: Every four days for 6 weeks. Method of measurement: Medical history taking.;Complications: reports of gastrointestinal discomfort, nausea, vomiting, lethargy, constipation, diarrhea by the patient. Timepoint: Every week for 6 weeks. Method of measurement: Medical history taking.;Serum ketones: the amount of ketones released in the blood. Timepoint: Before starting the study and every day for 6 weeks. Method of measurement: ketometery.
Secondary Outcome Measures
NameTimeMethod
Clinical response: T, N stage based on MRI. Timepoint: 6 weeks after the end of radiotherapy. Method of measurement: Doing pelvic MRI.
© Copyright 2025. All Rights Reserved by MedPath